Avatrombopag (Doptelet®). HTA ID: 20058
Avatrombopag is licensed for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 16/12/2020 |
| Rapid review completed | 15/02/2021 |
| Rapid Review outcome | A full HTA is not recommended. The NCPE recommends that avatrombopag not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.